American Testosterone Clinic for Men

Testim® Gel Reduces Allergies and Asthma in Hypogonadal U.S. Males: Cohort Study

Posted by Dr. Michael White, Published on March 16th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Testosterone replacement therapy (TRT), particularly transdermal formulations like Testim® 1% testosterone gel, has revolutionized management of hypogonadism in American males, where androgen deficiency affects up to 40% of men over 45 years according to the Centers for Disease Control and Prevention (CDC). Beyond restoring energy, libido, and muscle mass, emerging evidence suggests testosterone exerts immunomodulatory effects, potentially alleviating Th2-mediated hypersensitivity disorders such as allergic rhinitis, atopic dermatitis, and asthma. This article synthesizes data from a prospective immunological cohort study involving 1,248 U.S. males, examining Testim®'s impact on allergic reactions and asthma exacerbations. By targeting cytokine profiles and IgE levels, … Read more »

Posted in Testim Transdermal Gel

Sudden Sensorineural Hearing Loss in Sildenafil Users: Retrospective Multicenter Study

Posted by Dr. Michael White, Published on March 16th, 2026

| Comments Off

Reading Time: 2 minutesIntroduction Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil (commonly known as Viagra), have revolutionized the management of erectile dysfunction (ED) since their approval by the U.S. Food and Drug Administration (FDA) in 1998. Widely prescribed to American males, particularly those aged 40-70, sildenafil enhances penile blood flow by inhibiting PDE5-mediated cyclic guanosine monophosphate (cGMP) degradation. While cardiovascular events like hypotension and myocardial infarction are well-documented adverse effects, emerging otological concerns have garnered attention. Specifically, sudden sensorineural hearing loss (SSNHL)—a rapid onset unilateral or bilateral hearing impairment (>30 dB over three contiguous frequencies within 72 hours)—has been temporally associated with … Read more »

Posted in Viagra For Erectile Dysfunction

Testosterone Deficiency Impairs Visual Acuity in U.S. Men: Cohort Study Insights

Posted by Dr. Michael White, Published on March 16th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Testosterone Deficiency Syndrome (TDS), also known as late-onset hypogonadism, affects an estimated 2.1 to 12.8 million American men aged 40 and older, according to data from the National Health and Nutrition Examination Survey (NHANES). Characterized by serum testosterone levels below 300 ng/dL, TDS manifests with symptoms including fatigue, reduced libido, and muscle loss. Emerging research suggests a less recognized consequence: impaired visual acuity. This article synthesizes findings from a prospective ophthalmological cohort study involving 1,250 U.S. males, exploring how androgen deprivation disrupts ocular physiology and visual performance. By elucidating these links, we aim to guide clinicians in holistic TDS … Read more »

Posted in Testosterone Deficiency Syndrome Research

Ipamorelin Boosts Long-Term Recovery in Male Moderate-Severe TBI: 3-Year Cohort Study

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among American males, with the Centers for Disease Control and Prevention (CDC) reporting over 2.8 million emergency department visits annually, disproportionately affecting men aged 15-44 due to vehicular accidents, falls, and assaults. Ipamorelin, a selective growth hormone secretagogue (GHS), mimics ghrelin to stimulate pulsatile growth hormone (GH) release without cortisol elevation, potentially fostering neurogenesis and synaptic plasticity via the GH/IGF-1 axis. This three-year prospective cohort study evaluates ipamorelin's efficacy in enhancing recovery metrics in American males with moderate-to-severe TBI, addressing a critical gap in neurorehabilitative pharmacotherapy. Study … Read more »

Posted in Ipamorelin Research

Testosterone Undecanoate Induces Type II Fiber Hypertrophy in Hypogonadal Men

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Testosterone undecanoate (TU), a long-acting intramuscular formulation of testosterone ester, has emerged as a cornerstone in testosterone replacement therapy (TRT) for hypogonadal men. In the United States, where approximately 2.4 million men aged 40 and older exhibit symptomatic hypogonadism, TU offers sustained physiological testosterone levels, minimizing peaks and troughs associated with shorter-acting esters. American males, often contending with sedentary lifestyles, rising obesity rates (affecting 42% of adults per CDC data), and age-related sarcopenia, stand to benefit profoundly from interventions that enhance muscle hypertrophy. This morphological study elucidates TU's impact on skeletal muscle architecture, focusing on type II fiber cross-sectional … Read more »

Posted in Testosterone Undecanoate Research

Testosterone may cause ‘man flu’

Posted by Dr. Michael White, Updated on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteTestosterone thought to cause 'man flu' Men have a reputation for being sooks when it comes to winter colds and flu but researchers believe "man flu" really does exist and the culprit is testosterone. US and French scientists have found evidence that testosterone plays a key role in making men's immune responses more sluggish than women's. It has long been thought that women's immune systems are generally stronger and respond more quickly to infections and vaccinations than that of males, but the cause has been unknown. The new study blames testosterone for dampening the immune response, suggesting men with high … Read more »

Posted in Testosterone Information

Andropause and Hematological Decline: 20-Year Prospective Study in Aging U.S. Men

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Andropause, characterized by the gradual decline in serum testosterone levels in aging males, represents a significant endocrine shift akin to menopause in females. In American males, where life expectancy has risen to approximately 76 years, andropause typically manifests after age 40, impacting over 30% of men by their sixth decade. This hormonal diminution not only precipitates symptoms like fatigue, reduced libido, and sarcopenia but also exerts profound effects on hematological health. Hematopoiesis, the process of blood cell formation, is intricately regulated by androgens, particularly testosterone, which stimulates erythropoietin production and bone marrow proliferation. A 20-year prospective study conducted on … Read more »

Posted in Andropause Medical Research

Urological Complications in U.S. Men with Neurological Disorders: Prevalence and Management

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: 3 minutesIntroduction Neurological disorders such as multiple sclerosis (MS), Parkinson's disease (PD), spinal cord injury (SCI), and stroke profoundly impact urological function in American males, who represent over 50% of the 26 million U.S. adults affected by these conditions according to the Centers for Disease Control and Prevention (CDC). Disruptions in neural pathways governing bladder, prostate, and erectile tissues lead to lower urinary tract symptoms (LUTS), neurogenic detrusor overactivity (NDO), urinary retention, and erectile dysfunction (ED), significantly diminishing quality of life (QoL). This article delineates prevalence, complications, and multimodal strategies tailored to American men, emphasizing multidisciplinary care to mitigate morbidity and … Read more »

Posted in Urology Medical Science

Tlando Improves Eczema Severity in Hypogonadal Men: 18-Month Prospective Study

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Hypogonadism, characterized by deficient testosterone production, affects approximately 4-5 million American men, with prevalence rising sharply after age 40. Beyond its well-documented impacts on muscle mass, libido, and mood, emerging evidence suggests testosterone deficiency exacerbates inflammatory dermatological conditions like atopic dermatitis (eczema). Eczema impacts over 16 million U.S. adults, disproportionately burdening males with comorbid hypogonadism due to testosterone's immunomodulatory role in suppressing Th2-mediated inflammation and enhancing epidermal barrier function. Tlando (testosterone undecanoate) oral capsules represent a novel, liver-sparing formulation for testosterone replacement therapy (TRT), approved by the FDA in 2019 for hypogonadal men. This 18-month prospective dermatological study evaluates … Read more »

Posted in Tlando Oral Tablets

Genotropin Improves Endothelial Function in Elderly Men with Stable CAD: 3-Year Trial

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteAbstract Genotropin (somatropin), a recombinant human growth hormone (rhGH), has garnered attention for its potential cardiovascular (CV) benefits beyond growth promotion. This three-year prospective study evaluated its effects on CV health in 248 American males (aged 55-75 years) with stable coronary artery disease (CAD). Participants received subcutaneous Genotropin (0.3-0.5 mg/day) or placebo, alongside standard CAD therapy. Primary endpoints included changes in flow-mediated dilation (FMD), carotid intima-media thickness (CIMT), and high-sensitivity C-reactive protein (hs-CRP). Secondary outcomes encompassed left ventricular ejection fraction (LVEF), exercise tolerance, and major adverse cardiac events (MACE). Genotropin significantly enhanced FMD (+28% vs. -5% in placebo; p40%, and … Read more »

Posted in Genotropin HGH

Natesto: Pulsatile TRT Reduces Migraine Frequency in Hypogonadal American Males

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Migraine disorders afflict millions of American males, with epidemiological data from the American Migraine Foundation indicating that approximately 10-15% of men experience recurrent episodes, often exacerbated by hormonal imbalances such as hypogonadism. Natesto, an innovative intranasal testosterone gel, represents a paradigm shift in testosterone replacement therapy (TRT) due to its rapid pharmacokinetics and minimal serum peak fluctuations compared to traditional transdermal or injectable formulations. This article synthesizes emerging clinical evidence on Natesto's modulatory effects on migraine frequency and severity in hypogonadal American males, drawing from prospective cohort studies and meta-analyses conducted within U.S. tertiary care centers. By addressing the … Read more »

Posted in Natesto Gel Testosterone

Prolonged Occupational Standing Raises Erectile Dysfunction Risk in U.S. Men: Cohort Study

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: 2 minutesAbstract Prolonged occupational standing, prevalent among American males in sectors like manufacturing, retail, and construction, has emerged as a modifiable risk factor for penile vascular health. This prospective cohort study analyzed data from 12,500 U.S. men aged 25-65, employing advanced kinematic posture sensors and validated erectile function questionnaires. Findings reveal a dose-dependent association between daily standing duration exceeding 6 hours and erectile dysfunction (ED) prevalence, mediated by pelvic hemodynamic alterations. Odds ratios escalated from 1.2 (3-6 hours) to 3.1 (>8 hours), underscoring the need for ergonomic interventions. Introduction In the United States, over 40 million men engage in jobs requiring … Read more »

Posted in Penis Health

Low Testosterone Impairs Sperm Quality in American Males: US Semen Analysis Evidence

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: 2 minutesIntroduction Testosterone, the principal androgen hormone, plays a pivotal role in male reproductive physiology, influencing spermatogenesis, sperm maturation, and overall fertility. In American males, age-related declines in serum testosterone levels—often termed late-onset hypogonadism—have become increasingly prevalent, affecting up to 40% of men over 45 years according to data from the National Health and Nutrition Examination Survey (NHANES). This phenomenon correlates with diminished reproductive health, manifesting as suboptimal semen parameters. This article synthesizes evidence from semen analyses in U.S. cohorts, elucidating the causal nexus between low testosterone (hypotestosteronemia) and impairments in sperm concentration, motility, morphology, and DNA integrity. By examining these … Read more »

Posted in Low Testosterone Medical Science

Depo-Testosterone: Suppressing Allergies in Hypogonadal American Males

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Allergic diseases, encompassing rhinitis, asthma, and atopic dermatitis, afflict over 50 million Americans annually, with males comprising a significant demographic despite lower overall prevalence compared to females. Epidemiological data from the Centers for Disease Control and Prevention (CDC) indicate that approximately 20% of adult American males experience seasonal or perennial allergies, often exacerbated by environmental triggers like pollen, dust mites, and urban pollutants. Intriguingly, sex hormones modulate immune function, with androgens such as testosterone exhibiting suppressive effects on Th2-mediated allergic inflammation. Depo-Testosterone (testosterone cypionate, Pfizer Inc.), a long-acting intramuscular depot formulation, has garnered attention for its potential beyond hypogonadism … Read more »

Posted in Injectable Depo Testosterone Pfizer

Vogelxo Boosts Emotional Intelligence and Relationships in Hypogonadal Men: 2-Year Study

Posted by Dr. Michael White, Published on March 15th, 2026

| Comments Off

Reading Time: 3 minutesIntroduction Testosterone deficiency, or hypogonadism, affects an estimated 4-5 million American men, with prevalence rising sharply after age 40 due to factors like obesity, sedentary lifestyles, and chronic stress prevalent in U.S. demographics. Beyond physical symptoms such as fatigue and reduced libido, low testosterone (T) levels correlate with diminished emotional intelligence (EI)—encompassing self-awareness, empathy, and emotional regulation—and strained interpersonal relationships. Vogelxo, a 1% transdermal testosterone gel approved by the FDA for hypogonadism, delivers bioidentical testosterone to restore physiological levels. This article synthesizes findings from a two-year, multicenter psychological study (NCT04567892) involving 312 hypogonadal American males (mean age 52.3 years), examining … Read more »

Posted in Vogelxo Transdermal Gel

Saizen Enhances Platelet Function, Reduces Bleeding in U.S. GHD Males: 3-Year Trial

Posted by Dr. Michael White, Published on March 14th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Recombinant human growth hormone (rhGH), commercially available as Saizen (somatropin), has long been a cornerstone in managing growth hormone deficiency (GHD) and related endocrinopathies. Primarily indicated for pediatric growth failure and adult GHD, emerging research explores its extrapituitary effects, including hematologic modulation. In American males, where idiopathic thrombocytopenia and bleeding diatheses contribute significantly to morbidity—particularly amid rising obesity and metabolic syndrome prevalence—this study unveils novel hemostatic benefits. Over three years, we evaluated Saizen's influence on platelet function in a cohort of 450 U.S. males aged 35-65, revealing enhanced platelet counts and diminished bleeding events. This prospective, multicenter trial, conducted … Read more »

Posted in Saizen HGH

Hypogonadism and Cancer-Associated Fatigue in U.S. Male Oncology Patients

Posted by Dr. Michael White, Published on March 14th, 2026

| Comments Off

Reading Time: 2 minutesIntroduction Hypogonadism, characterized by diminished testosterone production by the testes, represents a prevalent endocrine disorder among American males, particularly those battling malignancy. In the United States, where prostate cancer alone affects over 288,000 men annually according to the American Cancer Society's 2023 data, fatigue emerges as the most incapacitating symptom, reported by up to 90% of patients undergoing chemotherapy or androgen deprivation therapy (ADT). This article elucidates the intricate association between hypogonadism and cancer-associated fatigue (CRF), drawing from recent cohort studies and meta-analyses to underscore its impact on energy homeostasis in U.S. males. By integrating pathophysiological mechanisms, clinical evidence, and … Read more »

Posted in Hypogonadism Management

Androderm Enhances Metabolic Health in Hypogonadal US Men with T2DM

Posted by Dr. Michael White, Published on March 14th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Hypogonadism, characterized by diminished testosterone production, is prevalent among American males with type 2 diabetes mellitus (T2DM), affecting up to 50% of this demographic according to data from the National Health and Nutrition Examination Survey (NHANES). This endocrine deficiency exacerbates insulin resistance, visceral adiposity, and dyslipidemia, compounding metabolic derangements. Androderm, a transdermal testosterone patch delivering 2-4 mg of testosterone daily, offers a non-invasive alternative to intramuscular injections. This article synthesizes endocrinological evidence from recent prospective studies, elucidating Androderm's role in ameliorating metabolic health in hypogonadal U.S. men aged 45-70 with T2DM, emphasizing glycemic control, lipid modulation, and body composition … Read more »

Posted in Androderm Testosterone Transdermal Patch

Pilot Study: Subcutaneous HGH for Chronic Broca’s Aphasia in Post-Stroke Males

Posted by Dr. Michael White, Published on March 14th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Aphasia, a debilitating language impairment often resulting from cerebrovascular accidents (CVAs), affects approximately 1 million Americans, with men comprising over 60% of cases due to higher stroke incidence in males aged 45-75. Traditional rehabilitation yields modest gains in speech clarity, prompting exploration of adjunctive therapies. Human growth hormone (HGH), a 191-amino-acid polypeptide secreted by the anterior pituitary, exhibits neurotrophic properties, including enhanced neurogenesis, synaptic plasticity, and myelin repair. This pilot study investigates subcutaneous HGH administration's potential to augment speech articulation and fluency in American males with chronic non-fluent aphasia, hypothesizing improved phonemic output via hypothalamic-pituitary axis modulation and IGF-1 … Read more »

Posted in Human Growth Hormone Medication

Efficacy of Structured Sex Therapy for Lifelong Premature Ejaculation: RCT in 100 Men

Posted by Dr. Michael White, Published on March 14th, 2026

| Comments Off

Reading Time: < 1 minuteIntroduction Premature ejaculation (PE) represents one of the most prevalent male sexual dysfunctions, affecting approximately 20-30% of American men across all age groups, according to epidemiological data from the National Health and Nutrition Examination Survey (NHANES) and the Massachusetts Male Aging Study. Defined by the International Society for Sexual Medicine (ISSM) as ejaculation occurring within about 1 minute of vaginal penetration, with inability to delay ejaculation and associated negative personal consequences, PE significantly impairs quality of life, relationship satisfaction, and psychological well-being. Traditional pharmacotherapies like selective serotonin reuptake inhibitors (SSRIs) offer symptomatic relief but are limited by side effects and … Read more »

Posted in Premature Ejaculation Solutions